The mutation of p90RSK phosphorylation sites (Ser363/380) blocks PHI1-mediated effects on cell viability and migration, supporting a model where the pathological expression of PHI-1 elevates p90RSK stability, amplifying the ERK signaling in cancer cells [47] (Figure 2). Here, RPS6KA1 is linked to cancer.